# IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

> **NCT01885897** · PHASE1,PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 33 (actual)

## Conditions studied

- Acute Myelogenous Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Myelodysplastic Syndromes (MDS)
- Lymphoma
- Myeloma
- Chronic Lymphocytic Leukemia (CLL)
- Chronic Myelogenous Leukemia (CML)

## Interventions

- **BIOLOGICAL:** ALT-803

## Key facts

- **NCT ID:** NCT01885897
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-11
- **Primary completion:** 2019-07
- **Final completion:** 2020-07
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01885897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01885897, "IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01885897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*